L-缬氨酸-2,3,4,4,4,5,5,5-D8 | 35045-72-8

• 物质功能分类: 分析化学 - 标准品
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-缬氨酸-2,3,4,4,4,5,5,5-D8
• 中文别名: L-缬氨酸-D8
• 英文名称: L-valine-d₈
• 英文别名: L-Valine-d8；(2S)-2-amino-2,3,4,4,4-pentadeuterio-3-(trideuteriomethyl)butanoic acid
• CAS: 35045-72-8
• 化学式: C₅H₁₁NO₂
• 分子量: 125.084
• InChiKey: KZSNJWFQEVHDMF-AYWPRJOCSA-N

物化性质

• 熔点：
  295-300 °C (subl.) (lit.)
• 溶解度：
  酸水溶液（少量溶解）、碱水溶液（少量溶解）、甲醇（少量，加热）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• WGK Germany：
  1

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : L-Valine-d8
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 35045-72-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Chemical characterization : Isotopically labeled
Synonyms : L-2-Amino-3-methylbutanoic acid-2,3,4,4,4,5,5,5-d8
(S)-α-Aminoisovaleric acid-2,3,4,4,4,5,5,5-d8
Deuterated L-valine
Formula : C5D8H3NO2
Molecular Weight : 125,20 g/mol
CAS-No. : 35045-72-8
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas. hygroscopic
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 295 - 300 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx)
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated., The levorotary (l) forms of leucine, isoleucine, and valine have been found to
have tumor-promoting activity for bladder carcinomas.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  L-缬氨酸-2,3,4,4,4,5,5,5-D8 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  S -2-((S )-3-(4-氯苯基)-N'-((4-氯苯基)磺酰基)-4-苯基-4,5-二氢-1H-吡唑-1-羧酰亚胺基)-的合成3-(甲基-d 3 )丁酰胺-d5 ，八氘化 JD5037

  摘要：

  JD5037 (1) 是一种有效的、选择性的、外周作用的大麻素 (CB1 R) 受体反向激动剂。外周 CB1 受体拮抗剂/反向激动剂在治疗 2 型糖尿病、肥胖症和非酒精性脂肪性肝炎等代谢疾病方面具有巨大潜力。我们报告了八氘化 [2 H8 ]-JD5037 (S, S) (8) 及其 (S, R) 非对映异构体 (13) 从市售 L-缬氨酸-d8 起始材料的合成。[2 H8 ]-JD5037 化合物将用于在临床 ADME 研究期间对未标记的 JD5037 进行定量，并将用作 LC-MS/MS 生物分析标准。

  DOI：

  10.1002/jlcr.3521

文献信息

• Racemic β-Sheets as Templates for the Generation of Homochiral (Isotactic) Peptides from Aqueous Solutions of (<i>RS</i>)-Valine or -Leucine<i>N</i>-Carboxy- anhydrides: Relevance to Biochirogenesis
  作者：Irina Rubinstein、Gilles Clodic、Gerard Bolbach、Isabelle Weissbuch、Meir Lahav

  DOI：10.1002/chem.200801477

  日期：2008.12.8

  polymerization yields libraries of racemic oligopeptides enriched with isotactic diastereoisomers, together with oligopeptide sequences containing enantiomeric blocks of homochiral residues; 2) the short peptides self-assemble into racemic colloidal architectures that serve as regio-enantioselective templates in the ensuing process of chain elongation; 3) homochiral residues of the amino acids located

  作为我们的外消旋前体同手性肽生物手性生成程序的一部分，我们报告了在水溶液中外消旋缬氨酸或亮氨酸N-羧基酸酐聚合过程中，获得具有多达25个相同手性残基的同手性序列的肽的可行性，例如由胺引发。通过MALDI-TOF质谱法确定寡肽的组成，并通过MALDI-TOF MS / MS对样品上的一些手性非对映异构体的序列进行研究，其中样品的S对映异构体标记有氘原子。该过程包括几个步骤：1）在聚合反应的早期阶段，采用不对称诱导的马尔可夫机制，生成富含等规非对映异构体的外消旋寡肽文库，与含有同手性残基的对映异构体嵌段的寡肽序列一起；2）短肽自组装成消旋胶体结构，在随后的链延长过程中用作区域-对映体选择性模板；3）位于这些胶体聚集体外围的氨基酸的同手性残基发挥有效的对映体选择，这导致长等规寡肽的形成。肽的最终非对映异构体分布取决于模板的组成，而模板的组成取决于引发剂的浓度。等规肽的外消旋混合物可以通过使用α-
• Solid‐State NMR Characterization of Paramagnetic Bis( <scp>L</scp> ‐valinato)copper(II) Stereoisomers – Effect of Conformational Disorder and Molecular Mobility on ¹³ C and ² H Fast Magic‐Angle Spinning Spectra
  作者：Gábor Szalontai、Jasmina Sabolović、Marijana Marković、and Szabolcs Balogh

  DOI：10.1002/ejic.201402134

  日期：2014.7

  structure of the cis isomer was also reflected in the 13C and 2H MAS spectra. Variable-temperature 2H MAS spectra of differently deuterated ligand species, that is, the copper(II) complexes with L-[D2]valine, L-[D8]valine, and L-[D10]valine, suggested the dynamic nature of this disorder in the aqua cis isomer and confirmed static ND2 deuterons in the anhydrous trans isomer. Quantum chemical DFT/B3LYP calculations

  已获得顺磁性无水反式双 (L-valinato) 铜 (II) 和顺式水族双 (L-valinato) 铜 (II) 配合物的固态 13 C 和 2 H NMR 光谱。在非常快速的 MAS 条件下，13C 和 2H MAS 光谱都得到了很好的分离，可以轻松区分反式和顺式立体异构体。先前在顺式异构体的 X 射线结构中观察到的构象紊乱也反映在 13C 和 2H MAS 光谱中。不同氘化配体种类的变温 2H MAS 光谱，即铜 (II) 与 L-[D2] 缬氨酸、L-[D8] 缬氨酸和 L-[D10] 缬氨酸的配合物，表明了这种动态特性aqua 顺式异构体中的无序，并证实了无水反式异构体中的静态 ND2 氘核。
• CYP94B3 activity against jasmonic acid amino acid conjugates and the elucidation of 12-O-β-glucopyranosyl-jasmonoyl-l-isoleucine as an additional metabolite
  作者：Naoki Kitaoka、Hiroshi Kawaide、Naruki Amano、Takuya Matsubara、Kensuke Nabeta、Kosaku Takahashi、Hideyuki Matsuura

  DOI：10.1016/j.phytochem.2013.12.019

  日期：2014.3

  The hormonal action of jasmonate in plants is controlled by the precise balance between its biosynthesis and inactivation. Oxidation of jasmonoyl-L-isoleucine at the C-12 position, which is catalyzed by cytochrome P450s CYP94B3 and CYP94C1, is thought to be one of the main inactivation pathways. In this study, an additional function of CYP94B3 was elucidated, as well additional jasmonoyl-L-isoleucine metabolites being investigated. It was found that CYP94B3 also catalyzes the hydroxylation of jasmonoyl-L-valine and jasmonoyl-L-phenylalanine, and that these hydroxyl compounds accumulated after wounding and possessed lower activity than non-hydroxylated compounds. Additionally, 12-O-beta-glucopyranosyl-jasmonoyl-t-isoleucine accumulated after wounding, suggesting that it is a metabolite of